These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25549205)

  • 1. Therapeutic Drug Monitoring and Dose Adjustment of Posaconazole Oral Suspension in Adults With Acute Myeloid Leukemia.
    Hummert SE; Green MR
    Ther Drug Monit; 2015 Aug; 37(4):508-11. PubMed ID: 25549205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
    Liebenstein TK; Widmer KM; Fallon MJ
    J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
    Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies.
    Suh HJ; Kim I; Cho JY; Park SI; Yoon SH; Hwang JH; Bae JY; Lee JO; Koh Y; Song KH; Choe PG; Yu KS; Kim ES; Kim HB; Bang SM; Kim NJ; Song SH; Park WB; Oh MD
    Ther Drug Monit; 2018 Feb; 40(1):115-119. PubMed ID: 29189664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for subtherapeutic levels of posaconazole tablet.
    Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
    J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posaconazole plasma concentrations in critically ill patients.
    Ray J; Campbell L; Rudham S; Nguyen Q; Marriott D
    Ther Drug Monit; 2011 Aug; 33(4):387-92. PubMed ID: 21654350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis.
    Bryant AM; Slain D; Cumpston A; Craig M
    Int J Antimicrob Agents; 2011 Mar; 37(3):266-9. PubMed ID: 21236645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antifungal prophylaxis with oral suspension posaconazole during induction chemotherapy of acute myeloid leukemia.
    Schrenk KG; Schnetzke U; Stegemann K; von Lilienfeld-Toal M; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2015 Sep; 141(9):1661-8. PubMed ID: 25800622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
    Krishna G; AbuTarif M; Xuan F; Martinho M; Angulo D; Cornely OA
    Pharmacotherapy; 2008 Oct; 28(10):1223-32. PubMed ID: 18823218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing posaconazole plasmatic concentrations in patients presenting with acute myeloid leukemia.
    Desplanques PY; Burlacu R; Poinsignon V; Boussion H; Borget I; Wyplosz B; de Botton S; Billaud E; Chachaty E; Gachot B; Netzer F; Micol JB
    Med Mal Infect; 2014 Apr; 44(4):174-9. PubMed ID: 24656841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.
    van der Elst KC; Brouwers CH; van den Heuvel ER; van Wanrooy MJ; Uges DR; van der Werf TS; Kosterink JG; Span LF; Alffenaar JW
    Ther Drug Monit; 2015 Dec; 37(6):766-71. PubMed ID: 26565789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole therapeutic drug monitoring in the real-life setting: a single-center experience and review of the literature.
    Gross BN; Ihorst G; Jung M; Wäsch R; Engelhardt M
    Pharmacotherapy; 2013 Oct; 33(10):1117-25. PubMed ID: 23864486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
    Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients.
    Gubbins PO; Krishna G; Sansone-Parsons A; Penzak SR; Dong L; Martinho M; Anaissie EJ
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1993-9. PubMed ID: 16723557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Outcome of Antifungal Prophylaxis with Posaconazole in Patients with Acute Myeloid Leukemia: A Single-Center Study.
    Özkocaman V; Özkalemkaş F; Seyhan S; Ener B; Ursavaş A; Ersal T; Kazak E; Demirdöğen E; Mıstık R; Akalın H
    Turk J Haematol; 2018 Nov; 35(4):277-282. PubMed ID: 30047484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
    Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
    Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum posaconazole levels during acute myeloid leukaemia induction therapy: correlations with breakthrough invasive fungal infections.
    Cattaneo C; Panzali A; Passi A; Borlenghi E; Lamorgese C; Petullà M; Re A; Caimi L; Rossi G
    Mycoses; 2015 Jun; 58(6):362-7. PubMed ID: 25907298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.
    Krishna G; Sansone-Parsons A; Kantesaria B
    Curr Med Res Opin; 2007 Jun; 23(6):1415-22. PubMed ID: 17559737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Oral Suspension versus Delayed-Release Tablet Formulations of Posaconazole for Prophylaxis of Invasive Fungal Infections.
    Furuno JP; Tallman GB; Noble BN; Bubalo JS; Forrest GN; Lewis JS; Bienvenida AF; Holmes CA; Weber BR; McGregor JC
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.
    Vanstraelen K; Prattes J; Maertens J; Lagrou K; Schoemans H; Peersman N; Vermeersch P; Theunissen K; Mols R; Augustijns P; Annaert P; Hoenigl M; Spriet I
    Eur J Clin Pharmacol; 2016 Aug; 72(8):953-63. PubMed ID: 27066958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.